Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"...with a number of licensing agreements currently in the works through its four wholly owned subsidiaries serving the nicotine, hemp, pharmaceutical and cannabis industries."
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Via
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Viable and Effective Alternatives for Nicotine Delivery
- Results from second in vivo study of 2018 a success
- DehydraTECH™ had a 90.2 percent greater absorption rate in the first 10 minutes
- Clients are improving high-quality products through the enhancement of this drug delivery platform
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a company focused on developing and out-licensing its disruptive drug delivery platform DehydraTECH™, recently announced the results of its second in vivo study of 2018 evaluating this edible technology’s use as a nicotine delivery system (http://nnw.fm/dmD2T).
The study was carried out by a third-party laboratory, which discovered that the absorption of nicotine was significantly greater when delivered by DehydraTECH™. In comparison with the tested control, the DehydraTECH™ system delivered a 90.2 percent greater absorption rate in the first 10 minutes. Because smoking gets the drug into the body so quickly, the speed of absorption for this edible form of nicotine delivery is very important in the overall success of providing a smoking alternative.
Lexaria’s DehydraTECH™ drug delivery platform offers a solution to the high numbers of smoking-related deaths and diseases. According to the U.S. Centers for Disease Control and Prevention (CDC), six million people die every year worldwide as a result of smoking, and 30 times that are living with serious illnesses related to a history of smoking (http://nnw.fm/2CnPX).
This disruptive drug delivery platform has multiple uses. Lexaria out-licenses DehydraTECH™ to entities whose goal is to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. With eight patents and nearly 50 more pending worldwide, Lexaria is enhancing the high-quality products of clients, not competing with them. Clients are improving upon high-quality products by increasing absorption rates, as well as improving taste and smell of the final product.
Clients are utilizing this edible technology in chocolates, beverages, dissolvable infusion products and more. Eighty percent of the company’s total revenue in 2018 is anticipated to come from the licensing of DehydraTECH™, with a number of licensing agreements currently in the works through its four wholly owned subsidiaries serving the nicotine, hemp, pharmaceutical and cannabis industries.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cannabis infused beverages or edibles are not legal in Canada yet, so Hill Street is not selling any. They do have alcohol free wines and beers that are supposed to be very good. I haven't tried any, I live in Yukon and haven't seen any for sale here.
https://www.hillstreetbevco.com/shop
Lexaria Delivers Across the Blood Brain Barrier
https://www.potnetwork.com/news/delivering-cannabis-over-blood-brain-barrier
I think Hill Street (BEER) could be a real takeover candidate, you don't necessarily need a grower, you can buy the oil from any number of companies.
https://www.bnnbloomberg.ca/video/hill-street-beverage-co-looks-to-alcohol-alternatives-with-cannabis-infused-drinks~1472019
It's going to be a Wild Wild Week of Weed
https://www.bloomberg.com/news/videos/2018-08-24/canadian-marijuana-stocks-jump-on-report-diageo-discussing-deal-video
Everyone and their dog wants to bring a cannabis-infused beverage to market but as the interview notes, the problem is the long time for the effects to hit you and scientists are scrambling to solve a problem Lexaria already has the answer to. Nothing but upside for LXRP from here on in!
I'm holding both LXX/LXRP and GBLX. Lexaria has 72 million O/S GBLX has 198 million.
Also, there are their many patents and patents pending for marijuana. Right now everyone is focused on the growers, but with the recent FDA approval of GWPH's Epidiolex the focus is shifting to the medical side and companies like GB Sciences and Lexaria Biosciences will be the next hot item.
Good assessment, I'd call $3.00 a preliminary target.
Lets hope we can power through it, but don't be surprised if it takes some effort to breach this level.
First, we're going to have to break through strong resistance around the .37 cent 50 DMA.
Of course, Dr. Kaminski is the one doing the clinical study for GBLX.
https://www.stockwatch.com/News/Item.aspx?bid=U-C5286-U%3aGBLX-20180806&symbol=GBLX®ion=U
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
2018-08-06 05:30 ET - News Release
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
Canada NewsWire
LAS VEGAS, Aug. 6, 2018
This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial.
LAS VEGAS, Aug. 6, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells. Mounting evidence suggests that the inflammatory processes in the brain contribute to the pathologies of Parkinson's, Alzheimer's and HIV-Associated Neurocognitive Disorders. The human primary blood cell screens performed at MSU are state-of-the-science models for evaluating the effects of compounds on the human immune system and allow MSU researchers to assess both the toxicity and anti-inflammatory potential of GB Sciences' neuroprotective compounds, including their Parkinson's formulations and others.
"GB Sciences is honored to be working with Dr. Kaminski on this project. He pioneered studies of the effects of cannabis on the immune system," explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "More recently, Dr, Kaminski's work has centered around the immune modulating effects of cannabis consumption on HIV/AIDS patients. In 2017, he demonstrated a relationship between cannabis use and improved brain health in HIV/AIDS patients who used cannabis versus those who did not. Dr. Kaminski has further theorized that cannabis use by HIV/AIDS patients may reduce their risk of HIV-Associated Neurocognitive Disorder (HAND) by reducing levels of inflammatory white blood cells in their brains. This same neuroinflammation may be a major contributing factor in a number of related neurological disorders such as Parkinson's disease and Alzheimer's disease."
GB Sciences holds a formidable Intellectual Properties portfolio and has engaged the cooperation of top research Universities and CRO's to maximize its potential. Given the breadth and depth of the disease states covered by the portfolio, the Company has adopted a 'Best of Breed' approach to identify, engage, and develop the most effective team to research and create the needed formulations on a project by project basis.
"GB Sciences is very fortunate to be working with Dr. Kaminski on this important research and development project on our lead therapeutic compounds," said John Poss, CEO and Chairman of GB Sciences, Inc. "Our company is committed to working with top universities and CRO's to achieve our goal of helping to unlock the therapeutic potential of cannabis."
MSU has begun testing GB Sciences' neuroprotective compounds at their Institute for Integrative Toxicology, where Dr. Kaminski serves as Director.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, EVP, tom@gbsciences.com
View original content with multimedia:http://www.prnewswire.com/news-releases/michigan-state-universitys-dr-norbert-kaminski-begins-pre-clinical-study-of-gb-sciences-neuroprotective-cannabis-compounds-for-parkinsons-disease-300692139.html
SOURCE GB Sciences, Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/August2018/06/c5286.html
© 2018 Canjex Publishing Ltd. All rights reserved.
Marijuana really does have major ‘beneficial effects’ for people living with inflammatory bowel disease - as GB Sciences knows and has a patent pending! $GBLX #gbsciences #medicalcannabis #CBD #mmj https://bit.ly/2OQ97kI
https://www.lexariabioscience.com/news/lexaria-files-new-patent-application-for-enhancement-of-delivery-of-lipophilic-agents-across-the-blood-brain-barrier-and-methods-for-treating-central-nervous-system-disorders/
https://www.lexariabioscience.com/news/lexaria-files-new-patent-application-for-enhancement-of-delivery-of-lipophilic-agents-across-the-blood-brain-barrier-and-methods-for-treating-central-nervous-system-disorders/
With approximately 50 patents now granted or pending worldwide, the Company’s policy has evolved to continue to issue news releases on material patent filings and issuances, but not on every patent-related development.
Took them long enough. I don't know what they've been doing!
86,145,000 o/s for BEER
Key resistance level in Canuckland appears to be $2.40, we've pierced it 3 times in August but have been turned back each time.
Lexaria issues 355,000 shares for IP achievements
2018-08-07 14:36 ET - News Release
Mr. Alex Blanchard reports
LEXARIA AWARDS SHARE INCENTIVE RELATED TO RECENT PATENT ACHIEVEMENTS
Lexaria Bioscience Corp. has issued a total of 355,000 restricted common shares as required by executive consulting agreements, shared by the chief executive officer and the president of the company.
The shares are required to be issued upon certain intellectual property achievements, and patent application filings in March and April triggered the awards. As a result, 172,500 shares were awarded at an issue price of $1.24 (U.S.); and 182,500 shares were awarded at an issue price of $1.32 (U.S.). Cash compensation of $185,200 (U.S.), designed to offset tax liabilities from the share award, was also granted.
Lexaria currently has about 49 patents pending or granted around the world, and has fostered an internal environment of intellectual creativity, incentivizing employees and consultants for successful patent progress. One year ago, the company had only approximately 18 patents pending or granted.
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
Monday will be quiet, a holiday in Canuck land!
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aHEXO-2641171&symbol=HEXO®ion=C
FP says Molson taps into weed with Hydropothecary
2018-08-02 09:17 ET - In the News
See In the News (C-TPX) Molson Coors Canada Inc
The Financial Post reports in its Thursday, Aug. 2, edition that a new partnership between Molson Coors Brewing and The Hydropothecary comes as beer sales are stagnating, but it also anticipates a potentially "massive" market for cannabis-infused drinks that could pick up the slack. The Post's Geoff Zochodne writes that on Wednesday, Hydropothecary and Molson announced the formation of a joint venture that will work on developing those nonalcoholic, weed-injected beverages. The company is being set up ahead of Canada's planned legalization of recreational cannabis in October, as well as the expected sales of edible marijuana products next year. Hydropothecary chief executive officer Sebastien St-Louis says a dollar value on the potential market for cannabis-infused drinks has not yet been determined. However, he says, "We expect the revenue from adult-use cannabis beverage to be massive." The deal could also underscore the overall importance of edibles for Canada's coming cannabis market. The significance may be even more so for big brewers that were already under pressure from craft competitors. Molson says its deal with Hydropothecary aims to tap into "changing consumer needs and preferences."
© 2018 Canjex Publishing Ltd. All rights reserved.
ORIGINAL: Lexaria’s DehydraTECH Triples Bioavailability of CBD in Human Trial -- CFN Media
2018-08-03 09:00 ET - News Release
SEATTLE, Aug. 03, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Bioscience Corp. (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP). The company has spent the past several years focused on improving the bioavailability of cannabinoids, including CBD. Its DehydraTECH™ drug delivery platform has demonstrated significant improvements in bioavailability over conventional delivery methods — and its latest human clinical study confirmed these findings. Lexaria is now one of a very few select biotech companies to have completed a successful human clinical trial with cannabinoids.
The cannabidiol (CBD) market is projected to reach $2.1 billion by 2020, according to the Hemp Business Journal, which marks significant growth over last year’s roughly $200 million in revenue. Consumers and physicians are starting to realize the significant potential benefits of the cannabinoid in treating a wide range of disorders that can be tied back to the human endocannabinoid system and its far-reaching effects.
CBD Bioavailability Issues
There are many different cannabidiol (CBD) delivery methods available for consumers, patients, and physicians, including capsules, tinctures, vape oils, and even edibles, and each delivery method impacts the body in a different way. Most importantly, some delivery methods are associated with greater bioavailability — or the percentage of the compound that’s absorbed into the bloodstream after any other processing in the body.
Oral CBD supplements, such as capsules, edibles, and oils, must pass through the digestive system and circulate through the liver. These processes metabolize CBD and reduce the amount that ultimately reaches the bloodstream, thereby reducing the bioavailability. While there aren’t any studies about CBD bioavailability, there are some studies that have shown tetrahydrocannabinol (THC) bioavailability of between four and 20 percent for oral delivery.
Another common way to consume CBD is through inhalation using CBD vape oils. When a consumer vapes oil, CBD bypasses first-pass metabolism and enters the bloodstream through the lungs. THC studies have shown that this can enhance bioavailability to as much as 56 percent, although there is significant variance due to factors like how long the vapor is held in the lungs and the volume of inhalation for a given person.
DehydraTECH™ Approach
Lexaria’s DehydraTECH™ drug delivery platform aims to improve bioavailability, as well as make the dosing more predictable across individuals.
By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver (first pass metabolism). Early animal studies showed that this approach could significantly improve the bioavailability of cannabinoids.
On August 1, the company released the results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™ — a proprietary DehydraTECH™ powered CBD hemp oil capsule. The study looked at the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancements in 12 healthy male volunteers.
The study found that CBD absorption was more than three-times higher than the control at the 30 minute mark and continued to significantly surpass control blood level concentrations through the 360 minute measurements. Interestingly, the CBD absorption was even better than GW Pharmaceuticals’ (NASDAQ: GWPH) Mount Sinai study, which used much higher doses of 400mg and 800mg to achieve lower overall blood concentrations.
Looking Ahead
Lexaria Bioscience Corp.’s (OTCQX: LXRP) (CSE: LXX) DehydraTECH™ has consistently demonstrated superior bioavailability versus other products on the market. In addition to CBD, the company has been actively researching the drug delivery platform’s potential in improving the bioavailability of other cannabinoids and other drugs. It has over 40 patents pending and 8 patents granted around the world protecting these innovations, yielding significant licensing opportunities down the road.
For more information, visit the company’s website at www.lexariabiosciences.com.
Please follow the link to read the full article: http://www.cannabisfn.com/lexarias-dehydratech-triples-bioavailability-cbd-human-trial/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
https://www.stockwatch.com/News/Item.aspx?bid=Z-C:*MKTSHEL-2640216&symbol=*MKTSHEL®ion=C
Shell Summary for July 31, 2018
2018-07-31 20:55 ET - Market Summary
by Stockwatch Business Reporter
The TSX Venture Exchange gained a fraction to 706.91 Tuesday, but it ended the month down 33.05 points. Terry Donnelly's shell graduate, Hill Street Beverage Company Inc. (BEER: $0.205), began trading today. It reached an intraday high of 28 cents before closing at 20.5 cents on 2.25 million shares. Hill Street is a Toronto company that sells non-alcoholic beer and non-alcoholic wine.
In its fiscal year ended June 30, 2017, Hill Street lost $217,926 on revenue of $1.52-million. Then in the six months ended Dec. 31, 2017, it lost $605,932 on revenue of $972,088. Despite the increased loss, Hill Street boasts on its website that it has so far donated a total of $1.46-million to recipients including the Canadian Liver Foundation.
Charity is not the only trend that Hill Street follows. In April, the company began working with Lexaria Bioscience Corp. (LXX: $2.26) to come up with non-alcoholic, marijuana-infused beer and wine. Hill Street and Lexaria have disclosed neither the terms of their deal nor its progress, but Hill Street will issue 419,982 shares to Lexaria as partial compensation.
Hill Street's chief executive officer, Mr. Donnelly, was previously the chief marketing officer for Canada from 2013 to 2015 at MDC Partners Inc. (MDCA: $5.10 (U.S.)), a Nasdaq-listed advertising company. Before joining MDC, he worked at four recruitment agencies between 1988 and 2012. He was also the head of the compensation committee at a flight simulation and training company, Atlantis Systems Corp., from 2004 to 2008, and he hired officers for an investment firm, Terranova Capital Partners Inc., from 2005 to 2007. A man of many skills, Mr. Donnelly was also a director of Active Control Technology Inc., a telco equipment supplier, from 2007 to 2010.
Hill Street Beverage went public through Joanne Yan's third capital pool shell, Avanco Capital Corp. She listed this shell in March, 2017, with a $400,000 initial public offering at 10 cents. Avanco's IPO shareholders did not need to wait long for a qualifying transaction, and they were not rolled back. They likely appreciate Hill Street's chart today, with the stock having traded between 19.5 and 28 cents.
Mind you it only seems to have begun trading under the BEER symbol today, used to be Avanco Capital, so doesn't mean a lot.
Seems to be doing more for Hill Street share price (C-BEER) than Lexaria.
Should see results soon, like now! Positive results will be a real driver!
https://www.lexariabioscience.com/news/lexaria-announces-human-clinical-study-on-cbd-absorption-underway/
Chris Bunka-Coffee and Cannabis
I suspect that HMMJ has been using National Bank to purchase LXX shares.
National Bank has been the largest net purchaser of LXX shares in June.
Net 499,403.
Weird that they say they developed the technology, then they go on to say that it was licensed from Lexaria. But it's all good news!
It's been 11 months since the National Research Council began lab work with Lexaria's technology. They must have at least preliminary results by now you would think. Validation of the methodology of action of DeydraTech would be invaluable!